Etopozid Accord 20 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

etopozid accord 20 mg/ml koncentrat za raztopino za infundiranje

accord healthcare - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Etopozid Accord 20 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

etopozid accord 20 mg/ml koncentrat za raztopino za infundiranje

accord healthcare - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Etopozid Kabi 20 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

etopozid kabi 20 mg/ml koncentrat za raztopino za infundiranje

fresenius kabi oncology plc - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Etopozid Kabi 20 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

etopozid kabi 20 mg/ml koncentrat za raztopino za infundiranje

fresenius kabi austria gmbh. - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Etopozid Kabi 20 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

etopozid kabi 20 mg/ml koncentrat za raztopino za infundiranje

fresenius kabi austria gmbh. - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Etopozid Kabi 20 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

etopozid kabi 20 mg/ml koncentrat za raztopino za infundiranje

fresenius kabi austria gmbh. - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

Tecentriq Evropska unija - slovenščina - EMA (European Medicines Agency)

tecentriq

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Imfinzi Evropska unija - slovenščina - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - karcinom, pljučni pljuč - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

EPOSIN 20 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eposin 20 mg/ml koncentrat za raztopino za infundiranje

teva b.v. - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid

EBEPOSID 20 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ebeposid 20 mg/ml koncentrat za raztopino za infundiranje

ebewe pharma - etopozid - koncentrat za raztopino za infundiranje - etopozid 20 mg / 1 ml - etopozid